Circulating Angiogenic Factors and the Risk of Preeclampsia

New England Journal of Medicine

Volumn 350, Issue 7, 2004, Pages 672-683

  Levine, Richard J ^a   Maynard, Sharon E ^b   Qian, Cong ^c   Lim, Kee Hak ^b   England, Lucinda J ^a   Yu, Kai F ^a   Schisterman, Enrique F ^a   Thadhani, Ravi ^e   Sachs, Benjamin P ^b,d   Epstein, Franklin H ^b   Sibai, Baha M ^f   Sukhatme, Vikas P ^b   Karumanchi, S Ananth ^b,g  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Allied Technology Group   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CALCIUM; GROWTH FACTOR; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER; PLACENTA PROTEIN; PRODUCT PLACENTA GROWTH FACTOR; VASCULOTROPIN A;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN BINDING; RISK FACTOR; SMALL FOR DATE INFANT; BLOOD; BODY MASS; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; NONPARAMETRIC TEST; RISK; STATISTICAL MODEL;

ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; LOGISTIC MODELS; ODDS RATIO; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RISK FACTORS; STATISTICS, NONPARAMETRIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 10744227199     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa031884     Document Type: Article

References (25)

1. Walker JJ. Pre-eclampsia. Lancet 2000;356:1260-5.
2. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001;357:53-6.
3. Cockell AP, Learmont JG, Smarason AK, Redman CW, Sargent IL, Poston L. Human placental syncytiotrophoblast microvillous membranes impair maternal vascular endothelial function. Br J Obstet Gynaecol 1997;104:235-40.
4. Holzgreve W, Ghezzi F, Di Naro E, Ganshirt D, Maymon E, Hahn S. Disturbed feto-maternal cell traffic in preeclampsia. Obstet Gynecol 1998;91:669-72.
5. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) ma contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
6. Page NM, Woods RJ, Gardiner SM, et al. Excessive placental secretion of neurokinin B during the third trimester causes preeclampsia. Nature 2000;405:797-800.
7. Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002;160:1405-23.
8. Koga K, Osuga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88:2348-51.
9. Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003;88:5555-63.
10. Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for pre-dieting severe, early-onset preeclampsia. Obstet Gynecol 2003;101:1266-74.
11. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188:177-82.
12. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707-16.
13. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) and FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
14. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
15. Levine RJ, Esterlitz JR, Raymond EG, et al. Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods. Control Clin Trials 1996;17:442-69.
16. Levine RJ, Hauth JC, Curet LB, et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997;337:69-76.
17. Zhang J, Bowes WA Jr. Birth-weight-for-gestational-age patterns by race, sex, and parity in the United States population. Obstet Gynecol 1995;86:200-8.
18. Tjoa ML, van Vugt JM, Mulders MA, Schutgens RB, Oudejans CB, van Wijk IJ. Plasma placenta growth factor levels in mid-trimester pregnancies. Obstet Gynecol 2001;98:600-7.
19. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001;184:1267-72.
20. Su YN, Lee CN, Cheng WF, Shan WY, Chow SN, Hsieh FJ. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol 2001;97:898-904.
21. Thadhani R, Mutter W, Wolf M, et al. First trimester placental growth factor and soluble Fms-like tyrosine kinase 1 (sFlt-1) and risk for preeclampsia. J Clin Endocrinol Metab (in press).
22. Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998;179:1539-44.
23. Strevens H, Wide-Swensson D, Hansen A, et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG 2003;110:831-6.
24. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype: one cause of defective endovascular invasion in this syndrome? J Clin Invest 1997;99:2152-64.
25. Torry DS, Mukherjea D, Arroyo J, Torry RJ. Expression and function of placenta growth factor: implications for abnormal placentation. J Soc Gynecol Investig 2003;10:178-88.